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Abstract 
 
The advent of exome-sequencing since 2009 has contributed significantly towards 
new discovery of heritable germline mutations and de novo mutations for rare 
Mendelian disorders with hitherto unknown genetic etiologies. Exome-sequencing is 
an efficient tool to identify the disease mutations without the need of a multi-
generational pedigree. Sequencing a single proband or multiple affected individuals 
have been shown successful in identifying disease mutations, but parents would be 
required in the case of de novo mutations. In addition to heritable germline and de 
novo mutations, exome-sequencing has also been succeeded in unraveling somatic 
driver mutations for a wide range of cancers through individual studies or 
international collaborative effort such as the Cancer Genome International 
Consortium. By contrast, the application of exome-sequencing in complex diseases is 
relatively limited, probably it is prohibitive expensive when it were to be applied to 
thousands of samples to achieve the statistical power to rare or low frequency 
variants (<1%).  On top of research discoveries, the application of exome-sequencing 
as a diagnostic tool is also increasing evident. In this review, we summarize and 
discuss the progress in these areas for almost a decade. 
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Introduction 
 
The advent of next-generation sequencing (NGS) technologies and 
sequence/target enrichment methods, designed to be used in tandem to capture all 
the protein-coding regions or exons, and some regulatory regions in the human 
genome, have ensured that the exome-sequencing approach is both technically 
feasible and cost-effective. This was amply demonstrated in the first publication to 
utilize exome-sequencing in an exploratory diagnostic context, an analysis that 
succeeded in identifying the known causal mutation for Freeman-Sheldon syndrome 
(Ng et al. 2009). This report spawned an exponentially increasing number of 
publications employing exome-sequencing to decipher the genetic basis of a range 
of human inherited diseases and sporadic cancers due to somatic mutations (Zhang 
2014; Rabbani et al. 2012).  
Since exome-sequencing is an approach that targets selected genomic 
regions, sequence enrichment is a prerequisite for library construction. The 
enrichment process is generally accomplished by means of PCR amplification and 
probe-target hybridization. In PCR amplification, primers are designed specifically for 
amplification, whereas probe-target hybridization employs probes to capture the 
targeted regions. Currently, exome enrichment methods are available from 
commercial vendors such as Agilent (e.g. SureSelect Human All Exon kit v4+UTR), 
NimbleGen (e.g. SeqCap EZ Human Exome v3) and Illumina (Nextera Rapid Capture 
Expanded Exome). Although exome enrichment generally focuses on protein coding 
regions, other important gene regulatory regions may also be included such as 
promoters, 5͛UT‘s and microRNAs, to enhance the potential for genetic discovery. 
Enrichment is essential for exome-sequencing. However, owing to the different 
efficiencies of both PCR amplification and probe hybridization, and the large number 
of genomic regions to be analysed, differential enrichment can ensue, thereby 
contributing to an uneven sequencing depth. This factor, together with sequencing 
and alignment biases, and the properties of the DNA sequence itself (e.g. GC-rich 
regions); can give rise to incomplete coverage in exome-sequencing. Generally, only 
80-90% of the targeted regions are sequenced to an adequate sequencing depth i.e. 
30-50x coverage for studies of germline variants (Meienberg et al. 2015; Chilamakuri 
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et al. 2014; Asan et al. 2011; Clarke et al. 2011). As a result of the biases introduced 
during enrichment for exome-sequencing, it requires a much higher sequencing 
depth compared to whole genome sequencing in order to achieve comparable 
performance in terms of the proportion of the coding regions to be covered 
sufficiently. For example, almost 98% of the coding regions have a minimal coverage 
of 20x when the whole genome was sequenced at an average of 87x depth, but not 
for exome-sequencing (Lelieveld et al. 2015). The proportion of false-positive single 
nucleotide variants (SNVs) was also found to be significantly higher for exome-
sequencing (78%) than for whole genome sequencing (17%). However, these figures 
should be interpreted carefully in the context of several factors in the study design, 
which could potentially contribute to the difference e.g. the sequencing coverage, 
QC criteria, and analysis (Belkadi et al. 2015). Although it would appear that 
sequencing the whole genome has advantages in terms of these technical 
performance aspects (i.e. coverage of the coding region and SNV detection), this also 
comes at a cost (and other formidable challenges such as analysis and 
interpretation).  
Therefore, with the limitations of the current exome-sequencing approach 
resulting in the preseŶĐe of ͚gaps͛ in the coding region coverage, interpretation of 
the results must be cautious, because incomplete coverage has the potential to 
compromise the sensitivity of variant detection. Indeed, true pathogenic variants 
might be missed in those regions with inadequate sequencing depth, leading to false 
negative results. This has important implications when exome-sequencing is applied 
͚agŶostiĐallǇ͛ for discovery purposes in the context of diseases with unknown genetic 
etiology, where the disease mutations might easily go undetected. To address this 
issue, the overall (or average) sequencing depth should be increased, so as to ensure 
that the least sequenced regions are adequately covered. Alternatively, conventional 
PCR amplification and Sanger sequencing might be needed to sequence those 
regions characterized by a low sequencing depth (Sims et al. 2014).  
In this article, we provide an overview of exome-sequencing and its 
applications in unraveling inherited germline and de novo mutations for Mendelian 
disorders, identifying somatic driver mutations in cancer, deciphering the genetics of 
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complex diseases, as well as its application as a diagnostic tool. We also discuss the 
contribution of exome-sequencing to new discoveries over the past 7 years.  
 
Discovering germline variants for rare Mendelian disorders 
Since the first proof-of-concept study employed exome-sequencing to 
identify the causal mutation for a rare Mendelian disorder, this strategy has been 
successfully replicated to elucidate the genetic basis of a considerable number of 
rare disorders e.g. Kabuki syndrome and Schinzel-Giedion syndrome (Bamshad et al. 
2011; Ku et al. 2011). Once the variants are called in the exomes, the list of variants 
is shortened in the analysis pipeline by filtering against common SNVs derived from 
general population databases such as the 1000 Genomes Project, to identify the 
disease mutations. In general, non-protein-altering SNVs are also removed so that 
non-synonymous SNVs are exclusively prioritized in the first tier analysis. This 
strategy would inevitably preclude the capture of regulatory regions for sequencing. 
In order not to exclude variants of potential pathological significance, in the 
regulatory regions, promoters, UTRs, intron-exon splice sites should also be 
analyzed. Further filtering to identify causal mutations depends upon the mode of 
inheritance; for example, with a recessive disorder, one would necessarily focus on 
homozygous and compound heterozygous SNVs (Ben-Omran et al. 2015; Parolin et 
al. 2015; Chong et al. 2015). Single nucleotide polymorphism (SNP) information 
embedded within the exome-sequencing data has also been used for homozygosity 
mapping or analysis; this is important in order to narrow down regions harboring the 
mutations underlying recessive disorders (Carr et al. 2013).  
Various bioinformatics tools, such as PolyPhen, SIFT and PhyloP, have also 
been used to predict the functional effects on the corresponding proteins of the 
SNVs and to ascertain the evolutionary conservation of the affected 
nucleotides/codons. There are strengths and shortcomings associated with the use 
of these individual predictive tools when applied alone, and sometimes the 
prediction results of these tools are inconsistent with each other (Dong et al. 2015). 
Thus, a new in silico bioinformatics tool has recently been developed with a better 
predictive power for the deleteriousness of mutations or disease causing mutations 
(Wu et al. 2014). This tool, known as SPRING (SnvPRioritization via the INtegration of 
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Genomic data), takes advantage of existing methods by integrating the functional 
effect scores calculated by SIFT, PolyPhen2, LRT, MutationTaster, GERP and PhyloP 
to predict disease SNVs. Additional association scores derived from a variety of 
genomic data sources such as gene ontology, protein-protein interactions, protein 
sequences, protein domain annotations and gene pathway annotations, were also 
included in the predictive model to further enhance its power to identify disease 
causing SNVs.  
Exome-sequencing has been shown to work well for rare disorders which 
have previously been refractory to traditional linkage analysis. This is because the 
sequencing of unrelated probands, and comparison with their non-affected family 
members (if available), has been shown to be successful without the need for a 
multi-generational pedigree (Bamshad et al. 2011; Ku et al. 2011). Exome-
sequencing has also been successful in identifying pathogenic mutations even in 
those cases where only a single patient is available. One of the first such successes 
was in the identification of two mutations impacting the MTHFD1 gene in an infant 
with an inborn error of folate metabolism affecting the MTHFD1 protein (Watkins et 
al. 2011). Exome-sequencing was performed on the single proband; the variants 
detected were first functionally annotated using a bioinformatics tool (i.e. 
ANNOVAR) and only those predicted to alter the amino acid sequence (namely non-
synonymous SNVs, short indels and splice site SNVs) were retained for further 
analysis. In the next phase of filtering, common variants were removed; such 
variants are most unlikely to be the disease mutations themselves because of the 
rarity of the clinical phenotype. Finally, only those variants which were either 
homozygous or compound heterozygous were retained so as to identify the disease 
mutations because an autosomal recessive pattern of the disorder was suspected.  
This series of filtering steps led to the identification of variants located in five 
different genes, namely BRD4, MTHFD1, PCSK4, TBC1D3C and TTLL8. In order to 
identify the pathogenic mutations, further sequencing of these variants in the 
proďaŶd͛s pareŶts aŶd the unaffected sibling was performed using Sanger 
sequencing. The mutations in TBC1D3C and BRD4 were considered to be false 
positives whereas PCSK4 was excluded because the unaffected sibling also inherited 
the same genotype as the patient, suggesting no involvement in pathology. Of the 
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two remaining genes, MTHFD1 was the most plausible candidate biologically, as it 
encodes a protein that is involved in cellular folate metabolism. Two mutations were 
identified in this gene, which were present in the compound heterozygous state in 
the patient; it was confirmed that the parents were heterozygous for each mutation 
respectively. In summary, this study demonstrated the power of the exome-
sequencing approach for the discovery of novel disease mutations even when only a 
single patient was available for analysis (Watkins et al. 2011).  
 In addition to identifying heritable germline mutations underlying Mendelian 
disorders, exome-sequencing has also been shown to be a powerful technique for 
unraveling de novo mutations. The genetic etiologies of such Mendelian disorders 
occur sporadically in families had been largely elusive until the advent of the exome-
sequencing approach. For dominant disorders, de novo mutations are commonly 
identified by sequencing trios of probands, the de novo mutations are detected in 
the probands but are, by definition, absent in their parents (Veltman et al. 2012; Ku 
et al. 2013a). One of the first studies to successfully identify disease-causing de novo 
mutations was in the context of Coffin–Siris syndrome. This is a rare congenital 
anomaly syndrome in which the majority of affected individuals are sporadic cases, 
strongly implying a dominant genetic basis for the disorder with underlying de novo 
mutations (Santen et al. 2012; Tsurusaki et al. 2012). An important advantage of 
applying exome-sequencing directly to trios is that it shortens the list of variants 
quite considerably because of the very small number of de novo mutations occurring 
in protein coding sequences at every generation. The application of exome-
sequencing to study de novo mutations is not restricted to rare disorders, but has 
also been expanded to the study of more common conditions such as autism, 
schizophrenia and intellectual disability, which also led to exciting discoveries. De 
novo ǀariaŶts ǁere fouŶd iŶ ͚eǆĐess͛ among cases in these disorders (Ku et al. 
2013b).  
In addition to individual studies designed to identify the genetic causes of 
Mendelian disorders, large-scale collaborative efforts and consortia have also 
leveraged the recent technological advances e.g. Centers for Mendelian Genomics 
and The Undiagnosed Diseases Program (Stray-Pedersen et al. 2014; Gonzaga-
Jauregui et al. 2013). More than 140 papers have been published by the Centers for 
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Mendelian Genomics since its establishment 
(http://www.mendelian.org/publications). So, it is likely that discoveries of new 
causal mutations and genes underlying Mendelian disorders will continue apace. 
Identifying these causal mutations will not only enhance our understanding of the 
molecular pathology of Mendelian disorders, but the knowledge thereby obtained 
could also shed new insight into the common and complex forms of disorders (e.g. 
familial and complex forms of amyotrophic lateral sclerosis) involving similar genes 
and pathways. Knowledge of the underlying disease mutations will also facilitate the 
rapid and accurate diagnosis of Mendelian disorders and would be the first step 
toward developing novel therapeutics for treatment (Bamshad et al. 2012). 
 
Deciphering cancer genomics  
Another major application of exome-sequencing is in the field of cancer 
genomics, where it has been applied to a wide variety of cancer types resulting in 
the identification of recurrent somatic mutations (Watson et al. 2013) and 
frequently mutated genes (Karageorgos et al. 2015). Studying somatic mutations in 
cancer is very different from identifying germline variants, as it requires a 
considerably higher depth of sequencing to allow for tissue and genetic 
heterogeneity. This heterogeneity dilutes the signal from the somatic mutations, 
resulting in lowered frequencies of the mutations in the tumor tissue. The extent of 
the heterogeneity depends on the purity of the tumor tissue and the vagaries of the 
process of clonal evolution of the mutations; on average, the detection of a somatic 
mutation requires 500 – 1000x sequencing depth to achieve the necessary levels of 
sensitivity and specificity. It follows that sequencing of the entire cancer genome to 
this depth might be prohibitively expensive when scaled up to a larger sample size 
(Mwenifumbo et al 2013). Sequencing an adequate number of samples is important 
to identify recurrent mutations (i.e. identical mutations in multiple samples) or 
frequently mutated genes (i.e. different mutations are detected in the same genes in 
different samples). One example is the identification of frequently mutated genes 
such as TP53, PIK3CA and ARID1A by the exome-sequencing of 15 gastric 
adenocarcinomas (Zang et al. 2012). A recent study also identified recurrent 
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mutations in the tumor suppressor gene CDC27 in an exome-sequencing study of 42 
testicular germ cell tumors (Litchfield et al. 2015).  
As in the context of other diseases, international collaborative efforts have 
accelerated the discovery of both driver mutations and cancer-associated genes, and 
initiated the process of deciphering the mutational landscape of different cancers to 
obtain an understanding of the underlying molecular biology. One of the largest 
cancer sequencing studies was performed as part of The Cancer Genome Atlas 
(which is an international collaborative effort to decipher he mutational landscape of 
a wide range of cancers), of which 4,742 tumor-normal pairs across 21 cancer types 
were analyzed (Lawrence et al. 2014). Somatic mutations in exome were analyzed 
and identified 33 novel genes that significantly mutated in cancer. This new set of 
genes revealed multiple pathways, which are important to understand the 
pathogenesis of cancer including genes related to cell proliferation, apoptosis, 
genome stability, chromatin regulation, immune evasion, RNA processing and 
protein homeostasis.  
The International Cancer Genome Consortium was also established to 
sequence 50 different cancer types and subtypes in thousands of samples 
(International Cancer Genome Consortium 2010). In addition to whole-genome 
sequencing, exome-sequencing was also applied; this ͚hǇďrid approaĐh͛ allows an in-
depth interrogation of somatic mutations in protein coding regions, at the same time 
as interrogating other mutations beyond the exome, and detecting structural 
rearrangements that would otherwise only be possible by employing the whole-
genome sequencing approach (Nakagawa et al. 2015). This was nicely exemplified in 
identifying a novel insertional translocation on chromosome 17 that generated a 
pathogenic PML–RARA gene fusion when whole genome sequencing was applied to 
a patieŶt͛s leukemic bone marrow. This type of complex rearrangement would not 
have been detected by exome-sequencing approach, further demonstrating that 
whole genome sequencing represents a comprehensive analytical tool for the entire 
genome. Furthermore, this finding has important clinical implications confirming a 
diagnosis of acute promyelocytic leukemia and for the administration of appropriate 
treatment for the patient (Welch et al. 2011).  
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In addition to identifying somatic driver mutations for sporadic cancer, 
exome-sequencing was also succeeded in revealing new genes for familial form of 
cancer (Noetzli et al. 2015; Calvete et al. 2015; Comino-Méndez et al. 2011; Jones et 
al. 2009). Notably, it was applied to sequence 51 individuals with multiple colonic 
adenomas from 48 families identifying a homozygous germline nonsense mutation in 
the base-excision repair gene namely NTHL1. This mutation was found in seven 
individuals from three families. Homozygosity of the mutation is consistent with the 
recessive inheritance of the adenomatous polyposis phenotype and progression to 
colorectal cancer showed in the three families. In contrast, the homozygote 
mutation was totally absent in controls i.e. the mutation was exclusively found in a 
heterozygous state in 2,329 controls, providing further evidence supporting its 
pathogenicity (Weren et al. 2015). Similar approach also led to the identification of 
new genes for other familial cancers such as MDH2 for familial paraganglioma 
(Cascon et al. 2015), and POT1 for familial glioma (Bainbridge et al. 2015).  
 
Deciphering the genetic bases of complex diseases 
The application of exome-sequencing has been increasingly evident in the 
context of both Mendelian disorders and cancer over the past few years. However, 
its application to dissecting the genetics of complex disease is still very limited (Wu 
et al. 2015). Exome-sequencing may be anticipated to identify rare SNVs with 
relatively large effect sizes (OR >2) associated with complex diseases, just as with 
genome-wide association studies (GWAS) which are primarily focused on common 
SNPs, but a significant proportion of the heritability of various complex phenotypes 
still remains unexplained. Applying exome-sequencing to hundreds or thousands of 
samples might require the effort of consortia, as has been amply demonstrated in 
the NHLBI (National Heart, Lung, and Blood Institute) Exome Sequence Project. 
Hundreds of ischemic stroke cases and controls were subjected to exome-
sequencing in the discovery phase, and then followed by genotyping with a larger 
sample size for replication purposes. This effort identified SNVs in two novel genes 
associated with an increased risk of ischemic stroke conferring a larger effect size 
(OR >2) as compared to earlier GWAS which identified SNP associations with ORs 
rarely exceeding 1.5 (Auer et al. 2015). Similar success was also achieved for other 
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diseases. When exome-sequencing was applied to 2869 amyotrophic lateral sclerosis 
cases and 6405 controls, this is also a large scale international collaborative 
endeavor which led to the identification of a new gene namely TBK1. The protein is 
known to bind to and phosphorylate a number of proteins involved in innate 
immunity and autophagy, thus revealing new pathogenesis pathways for the 
disease, and new targets for therapeutic interventions (Cirulli et al. 2015). As for age-
related macular degeneration, an association at a novel missense SNV in UBE3D 
gene was also found (Huang et al. 2015). Based on the same hypothesis that rare 
variants would be revealed via exome-sequencing, applying this approach to 9,793 
patients with myocardial infarction has also proven it by identifying rare SNVs in 
LDLR and APOA5 (Do et al. 2015).  
However, one of the factors hampering the widespread adoption of exome-
sequencing in the study of complex disease is likely to be the cost. This is because in 
order to attain the necessary statistical power to identify rare SNVs with larger effect 
sizes, thousands of samples would be required. As a result, utilizing exome arrays 
might represent a preferable option for GWAS. For example, the Infinium Human 
Exome BeadChip has been designed to genotype ~250,000 exonic SNVs representing 
diverse populations including European, African, Chinese, and Hispanic, and with the 
majority of SNVs having minor allele frequency <1%. This exome array has recently 
been applied in a very large scale study where >158,000 samples were genotyped 
(Wessel et al. 2015). As anticipated, focusing on rare exonic SNVs generated some 
novel findings. Indeed, a novel association of a low-frequency non-synonymous SNV 
in GLP1R was found to be associated with several phenotypes such as lower fasting 
glucose, type-2 diabetes and insulin secretion (Wessel et al. 2015). In similar vein, 
using the exome array genotyping approach, sixteen SNPs located in 15 new 
genes/loci were found to be associated with psoriasis (Zuo et al. 2015), and three 
low frequency missense variants were also found to be associated with an increased 
risk of lung cancer (Jin et al. 2015). 
Therefore, these studies have collectively showed that new discoveries could 
be made when a more focused and in depth approach (exome-sequencing or exome 
array genotyping) was applied to complex diseases. This is because exonic SNVs 
(especially the rare ones <1%) were not investigated comprehensively in the earlier 
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GWAS using whole-genome genotyping arrays based on linkage disequilibrium 
tagging SNP approach.  
 
Diagnostic applications 
The successful application of exome-sequencing is also evident in the context 
of disease diagnostics (Biesecker and Green 2014; Delanty and Goldstein 2013; Pyle 
et al. 2015; Sun et al. 2015). This was first shown in the diagnosis of congenital 
chloride-losing diarrhea in a patient suspected of having Bartter syndrome. Exome-
sequencing successfully identified a homozygous missense variant in SLC26A3, a 
gene already known to be responsible for the disease (Choi et al. 2009). Exome-
sequencing has also had a significant impact on patient management. This was nicely 
illustrated by the performance of an allogenic hematopoietic progenitor cell 
transplant in a child diagnosed with an X-linked inhibitor of apoptosis deficiency by 
exome-sequencing (Worthey et al. 2011).  
Recent studies have also shown that exome-sequencing yields promising 
results in the clinical setting when applied to severe intellectual disability, for which 
a ~16% diagnostic yield was reported (de Ligt et al. 2012). A higher success rate of 
~25% was reported by other studies for collections of different genetic conditions in 
large patient cohorts (Yang et al. 2014; Lee et al. 2014; Wright et al. 2015). More 
specifically, a molecular diagnosis rate of 25.2% was reported for 2000 patients 
(representing a collection of different suspected genetic conditions) whose exome-
sequencing tests were performed (Yang et al. 2014). When this collection of 
different genetic conditions was divided into different phenotypic or disease groups, 
it was found that the molecular diagnosis rate for ͚ŶeurologiĐal-related ĐoŶditioŶs͛ 
(i.e. conditions that affect development or function of the nervous system which 
included developmental delay, speech delay, autism spectrum disorder and 
intellectual disability) was higher (~27%) than ͚ŶoŶ-ŶeurologiĐal ĐoŶditioŶs͛ (~20%). 
In this study, only the patients were subjected to exome-sequencing, not their 
parents (Yang et al. 2014). 
On the other hand, sequencing child-parent trios is expected to yield a higher 
diagnostic rate for those diseases that are likely to be caused by de novo mutations, 
ďeĐause of the ͚Ŷature͛ of de novo mutations, which can only be detected with 
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parents being sequenced together. This has also been demonstrated when exome-
sequencing was performed on 814 patients with undiagnosed and suspected genetic 
conditions (Lee et al. 2014). These patients were divided into childhood and adult 
groups of which the most common clinical indication was developmental delay and 
ataxia respectively for the two groups. Two different approaches were applied to the 
patients and were cross-compared in terms of their clinical utility i.e. sequencing 
trios (both parents and their affected child), versus sequencing only the probands. 
Although the overall diagnosis rate for the 814 patients was 26%, there was a 
significant difference between the two approaches when applied to children with 
developmental delay. A rate of 41% was reported for sequencing the trios (for 
children with developmental delay), in contrast to only 9% for sequencing the 
probands alone (Lee et al. 2014). This marked difference in success rate was because 
de novo and compound heterozygous variants underlie the developmental delay 
phenotype; sequencing trios is a more effective way to detect such variants. This 
finding concurs with the findings of another study where the diagnostic rate was 
reported to be significantly higher in trios when exome-sequencing was applied to 
different genetic conditions such as ataxia, multiple congenital anomalies and 
epilepsy (Farwell et al. 2014) 
Although other approaches such as whole-genome and targeted-gene 
sequencing have also been explored in the context of diagnostics, there are several 
advantages in utilizing exome-sequencing. In comparison to the whole-genome 
approach, exome-sequencing is more cost-effective as it sequences only 1-2% of the 
whole human genome. It is also analytically less challenging, since the focus is 
narrowed down to the approximately 20,000 to 30,000 SNVs identified per exome. It 
is also more readily interpretable as the variants are identified in protein coding 
regions, the best-studied and most easily interpretable portion of the human 
genome (Biesecker and Green 2014; Sun et al. 2015). Although existing data showed 
that about 85% of the mutations identified in Mendelian disorders were found in the 
protein coding regions, this finding has to be interpreted with caution. This is 
because previous studies have been focused on identifying mutations within the 
protein coding regions; thus, by design, most if not all of the mutations identified 
would have been found in these regions. The proportion of all mutations underlying 
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the rare Mendelian disorders that reside in non-protein-coding regions remains 
unknown. This proportion can only be determined when whole genome sequencing 
is brought to bear (which, in passing, also highlights the shortcoming of exome-
sequencing in this context). Thus, in an attempt to generate a comprehensive view 
of all genetic variants (including noncoding variants, and structural variants), whole 
genome sequencing was applied to 16 unrelated patients with autosomal recessive 
retinitis pigmentosa. In addition to homozygous or compound heterozygous SNVs, 
there was a 2.3-kb deletion in USH2A and an inverted duplication of ∼446 kb in EYS, 
which would have been gone undetected using exome-sequencing (Nishiguchi et al. 
2013). Based on the motivation to explore beyond coding regions, whole genome 
sequencing was also applied to 85 quartet families (comprising parents and two-
affected siblings with autism spectrum disorder) to interrogate the association of 
non-coding variants for the disorder (Yuen et al. 2015).  
On the other hand, in comparison to the targeted-gene sequencing approach, 
exome-sequencing has been shown to be a powerful diagnostic tool for disorders 
characterized by a high degree of phenotypic/clinical heterogeneity, and/or locus 
heterogeneity (Xue et al. 2014; Rehm 2013). Disorders with phenotypic 
heterogeneity exhibit diverse clinical manifestations, which often overlap with other 
closely related disorders. This makes clinical diagnosis a challenging task, and yet an 
accurate clinical diagnosis is critical in guiding clinicians to select the correct disease-
specific test for molecular diagnosis or confirmation. Unlike exome-sequencing, a 
disease-specific test is often developed using the targeted-gene sequencing 
approach where only known disease genes are included. Exome-sequencing can also 
be applied to diseases characterized by locus heterogeneity, where mutations in 
numerous genes have been implicated, but where each gene may only account for a 
small proportion of cases; some cases may not be explicable in terms of mutations in 
known genes. For example, in both Charcot-Marie-Tooth disease and retinitis 
pigmentosa, tens of candidate genes have already been identified, but a large 
proportion of cases still cannot be accounted for by mutations in the known genes 
(Zhao et al. 2015). Similarly, by applying targeted sequencing of 579 genes 
associated with myopathy on 43 patients presenting with early onset neuromuscular 
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disorders with unknown genetic causes, only 32 patients were identified for known 
or novel pathogenic variants. This means that still a substantial number of patients 
remained without molecular diagnosis even a larger number of genes were tested 
(Chae et al. 2015). Thus, in such a scenario, exome-sequencing would play a critical 
role as a diagnostic tool, and for the discovery of new mutations or genes. This is the 
dual role of exome-sequencing as both a diagnostic and discovery tool (Ku et al. 
2012). Exome-sequencing is considered to be a ͚Đoŵmon or universal͛ diagŶostiĐ test 
applicable to all genetic disorders caused by mutations in protein coding regions. 
Such a test obviates the need to develop individual tests for each single disorder.  
Exome-sequencing is not however without its shortcomings. Sequencing all 
the protein coding regions increases the likelihood of generating incidental findings. 
These are the findings secondary to the original purpose of performing the genetic 
test. It is probably more straightforward if the incidental findings are clinically 
actionable, but it is controversial whether findings that are not clinically actionable 
should ďe disĐlosed ďǇ the ĐliŶiĐiaŶs ͚ďǇ default͛ or whether the patients have the 
right to opt for non-disclosure. In addition, clinicians should be trained to obtain 
informed consent from patients, how to address the thorny issue of clinically 
actionable incidental findings, as well as to interpret the genetic results (including 
variants of unknown significance) and communicate the findings to patients (Jurgens 
et al. 2015; Clarke 2014; Frebourg 2014; Boycott et al. 2015; Shashi et al. 2015; 
Amendola et al. 2015). Although exome-sequencing has been shown to be very 
promising as a diagnostic tool, there are still challenges for its widespread 
implementation in the routine clinical laboratory. Quite apart from the infrastructure 
required to support exome-sequencing testing in the routine laboratory situation, 
one must also acquire the capability to analyze the data and interpret the results so 
as to determine the pathogenicity or otherwise of new (i.e. previously unreported) 
protein altering variants detected in known disease genes (Johansen et al. 2014).  
The determination of the pathogenicity or otherwise of detected variants will 
often require further studies or the garnering of supporting evidence, such as 
observing the same variants in other patients with the same clinical phenotype, 
segregation analysis to show that the variants co-segregate with the affected family 
members, or in vitro studies to assess the functional impact of the variants. For 
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example, an amino acid changing mutation was identified in KCTD17 as the only 
exonic variant segregating in a dominant pedigree with seven individuals affected by 
myoclonus-dystonia (Mencacci et al. 2015). On the other hand, in vitro models such 
as using cell lines to demonstrate functional effects have also been commonly 
employed. This was demonstrated in the case of the identification of two 
homozygous mutations in PYCR2 causing microcephaly and hypomyelination, where 
a lymphoblastoid cell line from one affected individual showed a strong reduction in 
the amount of PYCR2 expression. Further, knockdown of a zebrafish PYCR2 ortholog 
yielded a phenotype resembling the human microcephaly phenotype. This was 
reversed by wild-type human PYCR2 mRNA, but not by mutant mRNAs, further 
supporting the case for the pathogenicity of the identified variants (Nakayama et al. 
2015).  
 
Conclusions 
Since its initial application, exome-sequencing has been widely applied, 
leading to major discoveries of novel mutations in particular Mendelian disorders 
(many hitherto uncharacterized molecularly) and cancer genetics. It is anticipated 
that this trend will continue, and should accelerate with the effort of international 
consortia. In addition to its widespread recruitment in research discovery, the role of 
exome-sequencing has also been shown to be a promising diagnostic tool in the 
clinical setting.  
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